Semaglutide, liraglutide and tirzepatide prefilled pens — the fastest-growing class in diabetes and obesity care.
GLP-1 receptor agonists are reshaping the treatment of type 2 diabetes and obesity worldwide. Artemisine Medicines Technology manufactures the three molecules that define the class: semaglutide (once-weekly 1.34 mg/mL prefilled pen), liraglutide (once-daily 6 mg/mL pen) and tirzepatide — the first GIP/GLP-1 dual agonist, in weekly single-dose pens from 2.5 mg to 15 mg.
These peptides demand exacting manufacture: sterile filling of multi-dose and single-dose pens, validated peptide assay and purity control (HPLC/LC-MS related-substance limits), and unbroken 2–8°C cold chain from our cleanroom to your warehouse. Our sterile workshop passed the 2026 China GMP on-site inspection, and every lot ships with COA, COPP, DMF and CTD-format dossiers.
For distributors and hospital groups, GLP-1 pens are offered with market-specific packaging, patient information leaflets and registration support — a factory-direct route into the fastest-growing therapeutic class in the world.
All products are GMP manufactured and supplied with COA, COPP, DMF and CTD dossiers. Tap any product for specifications and WHO prescribing guidance.
Tell us your target market and annual volume — our export team replies within 24 hours.
Semaglutide injection 1.34 mg/mL prefilled pen (once weekly), liraglutide injection 6 mg/mL prefilled pen (once daily), and tirzepatide injection — a GIP/GLP-1 dual agonist in 2.5–15 mg once-weekly pens.
Semaglutide and liraglutide are GLP-1 receptor agonists (weekly vs daily dosing); tirzepatide activates both GIP and GLP-1 receptors, delivering the largest HbA1c and weight reductions seen in class trials.
Sterile GMP filling, HPLC purity and assay control per batch, validated 2–8°C packaging with data-loggers, and retained samples kept one year beyond expiry for every batch.
Artemisine Medicines